Treatment and Prognosis of Patients With Chronic HBV Infection

Recruiting now

Conditions studied: Hepatitis B Virus Infection

In brief

Hepatitis B virus (HBV) infection is a major global health issue with 257 million chronically infected individuals. Of note, China has the largest population accounting for one third of the world's infected population. Approximately, about 300 000 people die each year due to the consequences of HBV. In 2016, the World Health Organization (WHO) proposed the goal for elimination of hepatitis B as public health threat by 2030 and China will be a major contributor towards this global goal. Currently, two approved therapeutic strategies are available including pegylated interferon (IFN) or nucleos (t) ide analogues (NA), which could suppress HBV replication and slow disease progression. Here, investigators hope to launch a cohort study to reveal the clinical features relating to therapeutic efficacy of antiviral therapy and the prognosis of patients with differential therapeutic strategies.

Key facts

Study ID

NCT05392387

Run by

Xiangya Hospital of Central South University

People needed

500

Starts

2021-10-25

Expected to finish

2026-10-25

Last updated by the study team

2022-05-26

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• patients with evidence of chronic HBV infection

You may not qualify if…

• chronic liver injury mainly caused by other reasons, such as autoimmune diseases, alcohol, drugs and so on.

Where it is running

• Department of Infectious Disease, Xiangya Hospital, Central South University — Changsha, Hunan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.